Allarithmin

Country of origin: Russia

Pharm-Group: Antiarrhythmic membrane-stabilizing agents of group 1C

Manufacturers: Novosibirsk Medical Preparations Plant (Russia)

International name: Lappaconitine hydrobromide

Synonyms: Allapinin

Dosage forms: tablets 25 mg

Composition: Active substance - lappaconitine hydrobromide.

Indications for use: Supraventricular and ventricular arrhythmias (extrasystoles, paroxysmal tachycardias), incl. against the background of myocardial infarction, paroxysms of supraventricular tachycardia in Wolff-Parkinson-White (WPW) syndrome, paroxysms of atrial fibrillation and flutter.

Contraindications: Hypersensitivity, atrioventricular block (AV) II and III degrees; severe liver failure, end-stage renal failure. Restrictions on use: AV (grade I) and intraventricular conduction disorders, sick sinus syndrome, heart failure, pregnancy.

Side effects: Headache, dizziness, facial hyperemia, diplopia, ataxia, tachycardia, electrocardiographic changes; allergic reactions. With prolonged use, sinus tachycardia may occur.

Interaction: Enhances the effect of non-depolarizing muscle relaxants.

Overdose: No information.

Special instructions: If headache, dizziness, or diplopia occur, the dose should be reduced. Repeated parenteral administration is allowed only after 6 hours. If sinus tachycardia occurs during long-term use, beta-blockers (low doses) are indicated. Prescribed with caution (mainly for health reasons) in the first 3 months of pregnancy. Prescription to patients with AV block of the first degree, sick sinus syndrome and severe heart failure is possible only in a hospital setting under medical supervision and ECG monitoring.

Literature: Encyclopedia of Medicines 2005.